Valproic acid resensitizes cisplatin-resistant ovarian cancer cells

Ching Tai Lin, Hung Cheng Lai, Hsin Yi Lee, Wei Hsin Lin, Cheng Chang Chang, Tang Yuan Chu, Ya Wen Lin, Kuan Der Lee, Mu Hsien Yu

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Although certain inhibitors of histone deacetylases have been shown to induce cytotoxicity alone or in combination with chemotherapeutic agents in cancer cells, the molecular mechanism is not clear. The goal of the present study was to determine whether the antiseizure drug valproic acid (2-propylpentanoic acid; VPA), which is also able to inhibit histone deacetylase, exhibits synergistic cytotoxicity with cisplatin, and the possible pathways for this. Our results clearly show that VPA not only exhibits synergistic cytotoxicity with cisplatin in all of the ovarian carcinoma cells tested, but also can resensitize the cells that have acquired resistance to cisplatin. Consistent with the increased cytotoxicity, cotreatment with VPA was shown to upregulate the cisplatin-mediated DNA damage revealed by phosphorylation of ataxia telangiectasia mutation and histone H2AX. Reactive oxygen species accumulation and tumor suppressor phosphatase and tensin homolog (PTEN) overexpression, which could contribute to the enhanced cytotoxicity, were also observed to be upregulated by VPA. Because PTEN knockdown by small interference RNA or antioxidant treatment can reduce cisplatin-mediated cytotoxicity, it is suggested that upregulation of PTEN and reactive oxygen species by VPA contributes to the enhancement of cisplatin-mediated cytotoxicity. These results with resensitization of cisplatin-resistant cells particularly may provide benefits in the treatment of ovarian cancer patients.

Original languageEnglish
Pages (from-to)1218-1226
Number of pages9
JournalCancer Science
Volume99
Issue number6
DOIs
Publication statusPublished - Jun 2008
Externally publishedYes

Fingerprint

Valproic Acid
Ovarian Neoplasms
Cisplatin
Phosphoric Monoester Hydrolases
Histone Deacetylases
Reactive Oxygen Species
Up-Regulation
Ataxia Telangiectasia
RNA Interference
Histones
DNA Damage
Neoplasms
Antioxidants
Phosphorylation
Carcinoma
Mutation
Therapeutics
Pharmaceutical Preparations
Tensins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lin, C. T., Lai, H. C., Lee, H. Y., Lin, W. H., Chang, C. C., Chu, T. Y., ... Yu, M. H. (2008). Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Science, 99(6), 1218-1226. https://doi.org/10.1111/j.1349-7006.2008.00793.x

Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. / Lin, Ching Tai; Lai, Hung Cheng; Lee, Hsin Yi; Lin, Wei Hsin; Chang, Cheng Chang; Chu, Tang Yuan; Lin, Ya Wen; Lee, Kuan Der; Yu, Mu Hsien.

In: Cancer Science, Vol. 99, No. 6, 06.2008, p. 1218-1226.

Research output: Contribution to journalArticle

Lin, CT, Lai, HC, Lee, HY, Lin, WH, Chang, CC, Chu, TY, Lin, YW, Lee, KD & Yu, MH 2008, 'Valproic acid resensitizes cisplatin-resistant ovarian cancer cells', Cancer Science, vol. 99, no. 6, pp. 1218-1226. https://doi.org/10.1111/j.1349-7006.2008.00793.x
Lin, Ching Tai ; Lai, Hung Cheng ; Lee, Hsin Yi ; Lin, Wei Hsin ; Chang, Cheng Chang ; Chu, Tang Yuan ; Lin, Ya Wen ; Lee, Kuan Der ; Yu, Mu Hsien. / Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. In: Cancer Science. 2008 ; Vol. 99, No. 6. pp. 1218-1226.
@article{436ed6a812714478a303014e131ffc0d,
title = "Valproic acid resensitizes cisplatin-resistant ovarian cancer cells",
abstract = "Although certain inhibitors of histone deacetylases have been shown to induce cytotoxicity alone or in combination with chemotherapeutic agents in cancer cells, the molecular mechanism is not clear. The goal of the present study was to determine whether the antiseizure drug valproic acid (2-propylpentanoic acid; VPA), which is also able to inhibit histone deacetylase, exhibits synergistic cytotoxicity with cisplatin, and the possible pathways for this. Our results clearly show that VPA not only exhibits synergistic cytotoxicity with cisplatin in all of the ovarian carcinoma cells tested, but also can resensitize the cells that have acquired resistance to cisplatin. Consistent with the increased cytotoxicity, cotreatment with VPA was shown to upregulate the cisplatin-mediated DNA damage revealed by phosphorylation of ataxia telangiectasia mutation and histone H2AX. Reactive oxygen species accumulation and tumor suppressor phosphatase and tensin homolog (PTEN) overexpression, which could contribute to the enhanced cytotoxicity, were also observed to be upregulated by VPA. Because PTEN knockdown by small interference RNA or antioxidant treatment can reduce cisplatin-mediated cytotoxicity, it is suggested that upregulation of PTEN and reactive oxygen species by VPA contributes to the enhancement of cisplatin-mediated cytotoxicity. These results with resensitization of cisplatin-resistant cells particularly may provide benefits in the treatment of ovarian cancer patients.",
author = "Lin, {Ching Tai} and Lai, {Hung Cheng} and Lee, {Hsin Yi} and Lin, {Wei Hsin} and Chang, {Cheng Chang} and Chu, {Tang Yuan} and Lin, {Ya Wen} and Lee, {Kuan Der} and Yu, {Mu Hsien}",
year = "2008",
month = "6",
doi = "10.1111/j.1349-7006.2008.00793.x",
language = "English",
volume = "99",
pages = "1218--1226",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Valproic acid resensitizes cisplatin-resistant ovarian cancer cells

AU - Lin, Ching Tai

AU - Lai, Hung Cheng

AU - Lee, Hsin Yi

AU - Lin, Wei Hsin

AU - Chang, Cheng Chang

AU - Chu, Tang Yuan

AU - Lin, Ya Wen

AU - Lee, Kuan Der

AU - Yu, Mu Hsien

PY - 2008/6

Y1 - 2008/6

N2 - Although certain inhibitors of histone deacetylases have been shown to induce cytotoxicity alone or in combination with chemotherapeutic agents in cancer cells, the molecular mechanism is not clear. The goal of the present study was to determine whether the antiseizure drug valproic acid (2-propylpentanoic acid; VPA), which is also able to inhibit histone deacetylase, exhibits synergistic cytotoxicity with cisplatin, and the possible pathways for this. Our results clearly show that VPA not only exhibits synergistic cytotoxicity with cisplatin in all of the ovarian carcinoma cells tested, but also can resensitize the cells that have acquired resistance to cisplatin. Consistent with the increased cytotoxicity, cotreatment with VPA was shown to upregulate the cisplatin-mediated DNA damage revealed by phosphorylation of ataxia telangiectasia mutation and histone H2AX. Reactive oxygen species accumulation and tumor suppressor phosphatase and tensin homolog (PTEN) overexpression, which could contribute to the enhanced cytotoxicity, were also observed to be upregulated by VPA. Because PTEN knockdown by small interference RNA or antioxidant treatment can reduce cisplatin-mediated cytotoxicity, it is suggested that upregulation of PTEN and reactive oxygen species by VPA contributes to the enhancement of cisplatin-mediated cytotoxicity. These results with resensitization of cisplatin-resistant cells particularly may provide benefits in the treatment of ovarian cancer patients.

AB - Although certain inhibitors of histone deacetylases have been shown to induce cytotoxicity alone or in combination with chemotherapeutic agents in cancer cells, the molecular mechanism is not clear. The goal of the present study was to determine whether the antiseizure drug valproic acid (2-propylpentanoic acid; VPA), which is also able to inhibit histone deacetylase, exhibits synergistic cytotoxicity with cisplatin, and the possible pathways for this. Our results clearly show that VPA not only exhibits synergistic cytotoxicity with cisplatin in all of the ovarian carcinoma cells tested, but also can resensitize the cells that have acquired resistance to cisplatin. Consistent with the increased cytotoxicity, cotreatment with VPA was shown to upregulate the cisplatin-mediated DNA damage revealed by phosphorylation of ataxia telangiectasia mutation and histone H2AX. Reactive oxygen species accumulation and tumor suppressor phosphatase and tensin homolog (PTEN) overexpression, which could contribute to the enhanced cytotoxicity, were also observed to be upregulated by VPA. Because PTEN knockdown by small interference RNA or antioxidant treatment can reduce cisplatin-mediated cytotoxicity, it is suggested that upregulation of PTEN and reactive oxygen species by VPA contributes to the enhancement of cisplatin-mediated cytotoxicity. These results with resensitization of cisplatin-resistant cells particularly may provide benefits in the treatment of ovarian cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=43549123821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549123821&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2008.00793.x

DO - 10.1111/j.1349-7006.2008.00793.x

M3 - Article

C2 - 18429963

AN - SCOPUS:43549123821

VL - 99

SP - 1218

EP - 1226

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 6

ER -